168 related articles for article (PubMed ID: 27930532)
1. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.
Yin Y; Xiang J; Tang S; Chen J; Yu Q; Zhang B
Medicine (Baltimore); 2016 Dec; 95(49):e5488. PubMed ID: 27930532
[TBL] [Abstract][Full Text] [Related]
2. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
Bouchet S; Poulette S; Titier K; Moore N; Lassalle R; Abouelfath A; Italiano A; Chevreau C; Bompas E; Collard O; Duffaud F; Rios M; Cupissol D; Adenis A; Ray-Coquard I; Bouché O; Le Cesne A; Bui B; Blay JY; Molimard M
Eur J Cancer; 2016 Apr; 57():31-8. PubMed ID: 26851399
[TBL] [Abstract][Full Text] [Related]
3. [A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].
Xu H; Ma L; Xu W; Guan W; Wang B; Li G; Miao Y; Li L; Chen H; Yu J; Wang Y; Sun L; Yang L; Zhang D; Li F; Zhi X; Wang J; Xu J; Xu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1271-1276. PubMed ID: 27928798
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
[TBL] [Abstract][Full Text] [Related]
6. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
[TBL] [Abstract][Full Text] [Related]
7. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.
Wu X; Li J; Zhou Y; Mao Y; Luo S; He X; Wang L; Shen Y; Zhang H; Yang L; Zhang J
Chemotherapy; 2018; 63(6):301-307. PubMed ID: 30836365
[TBL] [Abstract][Full Text] [Related]
8. Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report.
Tjhoi WEH; Li K; Shou CH; Yang WL; Yu JR
Medicine (Baltimore); 2019 Feb; 98(6):e14477. PubMed ID: 30732216
[TBL] [Abstract][Full Text] [Related]
9. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.
Xia Y; Chen S; Luo M; Wu J; Cai S; He Y; Chen X; Zhang X
Cancer; 2020 May; 126 Suppl 9():2054-2061. PubMed ID: 32293723
[TBL] [Abstract][Full Text] [Related]
10. Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.
Farag S; Verheijen RB; Martijn Kerst J; Cats A; Huitema AD; Steeghs N
Clin Pharmacokinet; 2017 Mar; 56(3):287-292. PubMed ID: 27435281
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
IJzerman NS; Groenland SL; Koenen AM; Kerst M; van der Graaf WTA; Rosing H; Beijnen JH; Huitema ADR; Steeghs N
Eur J Cancer; 2020 Sep; 136():140-148. PubMed ID: 32688207
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
13. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
Yoo C; Ryu MH; Kang BW; Yoon SK; Ryoo BY; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
J Clin Oncol; 2010 Mar; 28(9):1554-9. PubMed ID: 20177019
[TBL] [Abstract][Full Text] [Related]
14. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
16. Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.
Liu J; Chen Z; Chen H; Hou Y; Lu W; He J; Tong H; Zhou Y; Cai W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335376
[TBL] [Abstract][Full Text] [Related]
17. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
McAuliffe JC; Hunt KK; Lazar AJ; Choi H; Qiao W; Thall P; Pollock RE; Benjamin RS; Trent JC
Ann Surg Oncol; 2009 Apr; 16(4):910-9. PubMed ID: 18953611
[TBL] [Abstract][Full Text] [Related]
18. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
[No Abstract] [Full Text] [Related]
19. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
